Complement-Mediated Enhancement of Monocyte Adhesion to Endothelial Cells by HLA Antibodies, and Blockade by a Specific Inhibitor of the Classical Complement Cascade, TNT003

Transplantation

Volumn 101, Issue 7, 2017, Pages 1559-1572

  Valenzuela, Nicole M ^a   Thomas, Kimberly A ^a   Mulder, Arend ^b   Parry, Graham C ^c   Panicker, Sandip ^c   Reed, Elaine F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c True North Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPHYLATOXIN; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; HLA ANTIBODY; HLA ANTIGEN CLASS 1 ANTIBODY; MONOCLONAL ANTIBODY; PADGEM PROTEIN; TNT 003; UNCLASSIFIED DRUG; CD11B ANTIGEN; COMPLEMENT INHIBITOR; HLA A ANTIGEN; IMMUNOSUPPRESSIVE AGENT; SELP PROTEIN, HUMAN; TNT003;

ANTIBODY MEDIATED REJECTION; AORTIC ENDOTHELIAL CELL; ARTICLE; CELL ADHESION; CELL SURFACE; COMPLEMENT CLASSICAL PATHWAY; CONTROLLED STUDY; EXOCYTOSIS; HUMAN; HUMAN CELL; LEUKOCYTE MIGRATION; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TOXIN SYNTHESIS; CELL CULTURE; COCULTURE; DOSE RESPONSE; DRUG EFFECTS; ENDOTHELIUM CELL; IMMUNOLOGY; METABOLISM;

ANTIBODIES, MONOCLONAL; CELL ADHESION; CELLS, CULTURED; COCULTURE TECHNIQUES; COMPLEMENT C3A; COMPLEMENT C5A; COMPLEMENT INACTIVATING AGENTS; COMPLEMENT PATHWAY, CLASSICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; EXOCYTOSIS; HLA-A ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MACROPHAGE-1 ANTIGEN; MONOCYTES; P-SELECTIN;

EID: 85024475319     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001486     Document Type: Article

References (73)

1. Berry GJ, Burke MM, Andersen C, et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibodymediated rejection in heart transplantation. J Heart Lung Transplant. 2013;32:1147-1162.
2. Fedrigo M, Gambino A, Benazzi E, et al. Role of morphologic parameters on endomyocardial biopsy to detect sub-clinical antibodymediated rejection in heart transplantation. J Heart Lung Transplant. 2011;30:1381-1388.
3. Fishbein GA, Fishbein MC. Morphologic and immunohistochemical findings in antibody-mediated rejection of the cardiac allograft. HumImmunol. 2012;73:1213-1217.
4. Drachenberg CB, Torrealba JR, Nankivell BJ, et al.Guidelines for the diagnosis of antibody-mediated rejection in pancreas allografts-updated Banff grading schema. Am J Transplant. 2011;11:1792-1802.
5. Glanville AR. Antibody-mediated rejection in lung transplantation: turning myth into reality. J Heart Lung Transplant. 2013;32:12-13.
6. Kozlowski T, Rubinas T, Nickeleit V, et al. Liver allograft antibodymediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl. 2011;17: 357-368.
7. Kunugi S, Shimizu A, Ishii E, et al. The pathological characteristics of acute antibody-mediated rejection in DA-to-Lewis rat orthotopic liver transplantation. Transplant Proc. 2011;43:2737-2740.
8. Tinckam KJ, Djurdjev O, Magil AB. Glomerular monocytes predict worse outcomes after acute renal allograft rejection independent of C4d status. Kidney Int. 2005;68:1866-1874.
9. Wallace WD, Reed EF, Ross D, et al. C4d staining of pulmonary allograft biopsies: an immunoperoxidase study. J Heart Lung Transplant. 2005; 24:1565-1570.
10. Haas M. An updated Banff schema for diagnosis of antibodymediated rejection in renal allografts. Curr Opin Organ Transplant. 2014;19:315-322.
11. Jin YP, Valenzuela NM, Ziegler ME, et al. Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus. Am J Transplant. 2014; 14:806-819.
12. Li F, Zhang X, Jin YP, et al. Antibody ligation of human leukocyte antigen class I molecules stimulates migration and proliferation of smooth muscle cells in a focal adhesion kinase-dependent manner. Hum Immunol. 2011; 72:1150-1159.
13. Zhang X, Rozengurt E, Reed EF. HLA class I molecules partner with integrin β4 to stimulate endothelial cell proliferation and migration. Sci Signal. 2010;3:ra85.
14. Ziegler ME, Jin YP, Young SH, et al. HLA class I-mediated stress fiber formation requires ERK1/2 activation in the absence of an increase in intracellular Ca2+ in human aortic endothelial cells. Am J Physiol Cell Physiol. 2012;303:C872-882.
15. Jindra PT, Jin YP, Rozengurt E, et al. HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol. 2008;180: 2357-2366.
16. Jindra PT, Zhang X,Mulder A, et al. Anti-HLA antibodies can induce endothelial cell survival or proliferation depending on their concentration. Transplantation. 2006;82(1 Suppl):S33-35.
17. Yamakuchi M, Kirkiles-Smith NC, Ferlito M, et al. Antibody to human leukocyte antigen triggers endothelial exocytosis. Proc Natl Acad Sci U S A. 2007;104:1301-1306.
18. Valenzuela NM, Hong L, Shen XD, et al. Blockade of p-selectin is sufficient to reduce MHC I antibody-elicited monocyte recruitment in vitro and in vivo. Am J Transplant. 2013;13:299-311.
19. Morrell CN, Murata K, Swaim AM, et al. In vivo platelet-endothelial cell interactions in response to major histocompatibility complex alloantibody. Circ Res. 2008;102:777-785.
20. Thomas KA, Valenzuela NM, Reed EF. The perfect storm: HLA antibodies, complement, FcγRs and endothelium in transplant rejection. Trends Mol Med. 2015;21:319-29.
21. Valenzuela NM, Mulder A, Reed EF. HLA class I antibodies trigger increased adherence of monocytes to endothelial cells by eliciting an increase in endothelial P-selectin and, depending on subclass, by engaging FcgammaRs. J Immunol. 2013;190:6635-6650.
22. Jane-wit D, Manes TD, Yi T, et al. Alloantibody and complement promote t cell-mediated cardiac allograft vasculopathy through noncanonical nuclear factor-κB signaling in endothelial cells. Circulation. 2013; 128:2504-2516.
23. Wasowska BA, Lee CY, Halushka MK, et al. New concepts of complement in allorecognition and graft rejection. Cell Immunol. 2007;248:18-30.
24. Baldwin WM 3rd, Kasper EK, Zachary AA, et al. Beyond C4d: other complement-related diagnostic approaches to antibody-mediated rejection. Am J Transplant. 2004;4:311-318.
25. Thomas KA, Valenzuela NM, Gjertson D, et al. An anti-C1s monoclonal, TNT003, inhibits complement activation induced by antibodies against HLA. Am J Transplantation. 2015;15:2037-49.
26. AlMahri A, Holgersson J, Alheim M. Detection of complement-fixing and non-fixing antibodies specific for endothelial precursor cells and lymphocytes using flow cytometry. Tissue Antigens. 2012;80:404-415.
27. Haynes DR, Harkin DG, Bignold LP, et al. Inhibition of C5a-induced neutrophil chemotaxis and macrophage cytokine production in vitro by a new C5a receptor antagonist. Biochem Pharmacol. 2000;60: 729-733.
28. Soruri A, Riggert J, Schlott T, et al. Anaphylatoxin C5a induces monocyte recruitment and differentiation into dendritic cells by TNF-alpha and prostaglandin E2-dependent mechanisms. J Immunol. 2003; 171:2631-2636.
29. Jagels MA, Chambers JD, Arfors KE, et al. C5a-and tumor necrosis factor-alpha-induced leukocytosis occurs independently of beta 2 integrins and L-selectin: differential effects on neutrophil adhesion molecule expression in vivo. Blood. 1995;85:2900-2909.
30. Jagels MA, Daffern PJ, Hugli TE. C3a and C5a enhance granulocyte adhesion to endothelial and epithelial cell monolayers: epithelial and endothelial priming is required for C3a-induced eosinophil adhesion. Immunopharmacology. 2000;46:209-222.
31. Monk PN, Banks P. The role of protein kinase C activation and inositol phosphate production in the regulation of cell-surface expression of Mac-1 by complement fragment C5a. Biochim Biophys Acta. 1991; 1092:251-255.
32. Monk PN, Barker MD, Partridge LJ. Multiple signalling pathways in the C5a-induced expression of adhesion receptor Mac-1. Biochim Biophys Acta. 1994;1221:323-329.
33. Foreman KE, GlovskyMM,Warner RL, et al. Does complement activation control 'tissue trafficking' by C3a and C5a anaphylotoxin generation? Int Arch Allergy Immunol. 1995;107:394-395.
34. Foreman KE, Glovsky MM, Warner RL, et al. Comparative effect of C3a and C5a on adhesion molecule expression on neutrophils and endothelial cells. Inflammation. 1996;20:1-9.
35. Foreman KE, Vaporciyan AA, Bonish BK, et al. C5a-induced expression of P-selectin in endothelial cells. J Clin Invest. 1994;94:1147-1155.
36. Kilgore KS, Ward PA, Warren JS. Neutrophil adhesion to human endothelial cells is induced by the membrane attack complex: the roles of P-selectin and platelet activating factor. Inflammation. 1998;22: 583-598.
37. MulliganMS, Schmid E, TillGO, et al. C5a-dependent up-regulation in vivo of lung vascular P-selectin. J Immunol. 1997;158:1857-1861.
38. Valenzuela NM, Trinh KR, Mulder A, et al. Monocyte recruitment by HLA IgG-activated endothelium: the relationship between IgG subclass and FcγRIIa polymorphisms. Am J Transplant. 2015;15:1502-18.
39. Wright A, Morrison SL. Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mousehuman immunoglobulin G1. J ExpMed. 1994;180:1087-1096.
40. Mulder A, Kardol M, Blom J, et al. A human monoclonal antibody, produced following in vitro immunization, recognizing an epitope shared by HLA-A2 subtypes and HLA-A28. Tissue Antigens. 1993; 42:27-34.
41. Mulder A, KardolMJ, Arn JS, et al. Human monoclonal HLA antibodies reveal interspecies crossreactive swineMHC class I epitopes relevant for xenotransplantation. Mol Immunol. 2010;47:809-815.
42. Duquesnoy RJ, Marrari M, Jelenik L, et al. Structural aspects of HLA class I epitopes reacting with human monoclonal antibodies in Igbinding, C1q-binding and lymphocytotoxicity assays. Hum Immunol. 2013;74:1271-1279.
43. Park MS, LauM, Geer LI, et al. International sera exchange analyses in relation to DNA sequences: summary report from 1990 to 1994. Clin Transpl. 1994:489-508.
44. Ziegler-Heitbrock HW, Thiel E, Futterer A, et al. Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. Int J Cancer. 1988;41:456-461.
45. Shi J, Rose EL, Singh A, et al. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Blood. 2014;123:4015-4022.
46. Zwirner J, Fayyazi A, Gotze O. Expression of the anaphylatoxin C5a receptor in non-myeloid cells. Mol Immunol. 1999;36:877-884.
47. Monsinjon T, Gasque P, Chan P, et al. Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J. 2003;17:1003-1014.
48. Schraufstatter IU, Trieu K, Sikora L, et al. Complement c3a and c5a induce different signal transduction cascades in endothelial cells. J Immunol. 2002;169:2102-2110.
49. Burg M, Martin U, Bock D, et al. Differential regulation of the C3a and C5a receptors (CD88) by IFN-gamma and PMA in U937 cells and related myeloblastic cell lines. J Immunol. 1996;157:5574-5581.
50. Katona IM, Ohura K, Allen JB, et al. Modulation of monocyte chemotactic function in inflammatory lesions. Role of inflammatory mediators. J Immunol. 1991;146:708-714.
51. Burg M, Martin U, Rheinheimer C, et al. IFN-gamma up-regulates the human C5a receptor (CD88) in myeloblastic U937 cells and related cell lines. J Immunol. 1995;155:4419-4426.
52. Fletcher MP, Stahl GL, Longhurst JC. C5a-induced myocardial ischemia: role for CD18-dependent PMN localization and PMN-platelet interactions. Am J Physiol. 1993;265:H1750-1761.
53. Tyagi S, Klickstein LB, Nicholson-Weller A. C5a-stimulated human neutrophils use a subset of beta2 integrins to support the adhesiondependent phase of superoxide production. J Leukoc Biol. 2000;68: 679-686.
54. Burke-Gaffney A, Hellewell PG. A CD18/ICAM-1-dependent pathwaymediates eosinophil adhesion to human bronchial epithelial cells. Am J Respir Cell Mol Biol. 1998;19:408-418.
55. Stegall MD, Gloor JM. Deciphering antibody-mediated rejection: new insights into mechanisms and treatment. Curr Opin Organ Transplant. 2010;15:8-10.
56. Bentall A, Tyan DB, Sequeira F, et al. Antibody-mediated rejection despite inhibition of terminal complement. Transpl Int. 2014;27:1235-43.
57. Burbach M, Suberbielle C, Brocheriou I, et al. Report of the inefficacy of eculizumab in 2 cases of severe antibody-mediated rejection of renal grafts. Transplantation. 2014;98:1056-1059.
58. Orandi BJ, Zachary AA, Dagher NN, et al. Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection After HLAincompatible kidney transplantation. Transplantation. 2014;98:857-863.
59. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant. 2011;11:2405-2413.
60. Skeie JM, Fingert JH, Russell SR, et al. Complement component C5a activates ICAM-1 expression on human choroidal endothelial cells. Invest Ophthalmol Vis Sci. 2010;51:5336-5342.
61. Del Conde I, CruzMA, Zhang H, et al. Platelet activation leads to activation and propagation of the complement system. J Exp Med. 2005;201: 871-879.
62. Issekutz AC, Chuluyan HE, Lopes N. CD11/CD18-independent transendothelial migration of human polymorphonuclear leukocytes and monocytes: involvement of distinct and unique mechanisms. J Leukoc Biol. 1995;57:553-561.
63. Issekutz TB. In vivo bloodmonocytemigration to acute inflammatory reactions, IL-1 alpha, TNF-alpha, IFN-gamma, and C5a utilizes LFA-1, Mac-1, and VLA-4. The relative importance of each integrin. J Immunol. 1995; 154:6533-6540.
64. Cravedi P, Leventhal J, Lakhani P, et al. Immune cell-derived C3a and C5a costimulate human Tcell alloimmunity. AmJ Transplant. 2013;13:2530-2539.
65. Cravedi P, van der Touw W, Heeger PS. Complement regulation of T cell alloimmunity. Semin Nephrol. 2013;33:565-574.
66. Ghannam K, Martinez-Gamboa L, Spengler L, et al. Upregulation of immunoproteasome subunits in myositis indicates active inflammation with involvement of antigen presenting cells, CD8 Tcells and IFNGamma. PLoS One. 2014;9:e104048.
67. DeNicola MM, Weigt SS, Belperio JA, et al. Pathologic findings in lung allografts with anti-HLA antibodies. J Heart Lung Transplant. 2013;32: 326-332.
68. Magil AB, Tinckam K. Monocytes and peritubular capillary C4d deposition in acute renal allograft rejection. Kidney Int. 2003;63:1888-1893.
69. Xu L, Collins J, Drachenberg C, et al. Increased macrophage density of cardiac allograft biopsies is associated with antibody-mediated rejection and alloantibodies to HLA antigens. Clin Transplant. 2014;28:554-560.
70. Book WM, Kelley L, Gravanis MB. Fulminant mixed humoral and cellular rejection in a cardiac transplant recipient: a review of the histologic findings and literature. J Heart Lung Transplant. 2003;22:604-607.
71. Gaughan A, Wang J, Pelletier RP, et al. Key role for CD4 T cells during mixed antibody-mediated rejection of renal allografts. Am J Transplant. 2014;14:284-294.
72. Zeglen S, Zakliczynski M, Wozniak-Grygiel E, et al. Mixed cellular and humoral acute rejection in elective biopsies from heart transplant recipients. Transplant Proc. 2009;41:3202-3205.
73. Jindra PT, Hsueh A, Hong L, et al. Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts. J Immunol. 2008;180:2214-2224.